Investor profile
Advent Life Sciences has backed 6 European tech companies across 6 funding rounds between 2020 and 2025, joining rounds totalling €218M. Most active in Healthtech. Data as of 7 Aug 2026.
Hover a node for shared-deal counts; click a co-investor to open its profile.
Best viewed on a larger screen.
| Company | Country | Rounds | Total € |
|---|---|---|---|
| Proximie | UK | 1 | €77M |
| F2G | UK | 1 | €69M |
| Cyted Health | UK | 1 | €37M |
| Tridek-One | France | 1 | €16M |
| Epitopea | UK | 1 |
| Company | Stage | Amount | Date |
|---|---|---|---|
| Proximie | Series C | €77M | 2022-06 |
| F2G | Other | €69M | 2022-08 |
| Cyted Health | Series B | €37M | 2025-09 |
| Tridek-One |
| €12M |
| Amphista Therapeutics | UK | 1 | €6.7M |
| €16M |
| 2022-09 |
| Epitopea | Seed | €12M | 2022-04 |
| Amphista Therapeutics | Series A | €6.7M | 2020-07 |
